The evaluation of the anti-inflammatory effects of metformin in people with prediabetes and T2DM have shown that treatment with this agent resulted in decreased plasma insulin level, plasminogen activator type 1 (PAI-1) antigen, C- reactive protein (CRP) and fibrinogen [114]. The gene discussed is CRP; the disease is prediabetes syndrome.